After 20 years as Director of Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital focused on the development and clinical translation of novel targeted and gene therapies for children with brain cancer, Dr. Kieran transitioned to industry and is currently the VP of Clinical Development at Day One Biopharmaceutics, a company focused on the development of targeted drugs for children with cancer. With a PhD in Immunology from the University of Alberta, Canada and two post-doctoral fellowships in molecular biology (Paris, France) and cellular signal transduction (Harvard, Boston) as well as his sub-specialization in pediatric neuro-oncology, his career has focused on advancing our understanding of pediatric diseases, improving their treatment, educating the next generation of pediatric oncologists and ensuring greater access to treatments in developing countries. He continues to support a number of foundation scientific advisory boards reviewing grants and other funding proposals in additional to a number of educational initiatives. He helped develop and remains on the faculty of the Children’s Cancer Hospital Egypt, the largest pediatric cancer hospital in the world and he has a number of other initiatives to support the access of medicines to underserved populations including his role as CEO of Break Even Therapeutics, a 501c3 working to supply essential medicines to at need populations around the world.
